The researchers argue that the evidence used to approve the product — called Abilify MyCite — was not only weak, but failed to demonstrate the technology improves adherence, a key point if the goal is to improve health outcomes. In other public health news: neuron research, seasickness, surgery, scooter safety, broken heart syndrome, and more.

from Kaiser Health News https://ift.tt/2XTADXy

Related Posts:

0 comments:

Post a Comment

Popular Posts